Shares of Lupin Ltd reach all-time high price on acquiring …
Dec 31, 2024 · Shares of Lupin Ltd surged 2.38 per cent to ₹2,364.65 on the BSE at 11.27 AM and it reached an all-time high of ₹2,372.55 during the session.. Lupin Ltd., a global pharmaceutical company ...
Lupin Announcement, Latest News on Lupin - The Economic Times
Dec 27, 2024 · Lupin Share Price: Indian pharmaceutical giant Lupin gained US FDA approval for its generic version of Gilead Sciences' HIV drug Descovy. This win grants Lupin 180 days of shared exclusivity in the US market, a significant boost for the company.
Lupin Acquires Huminsulin from Lilly to Enhance Diabetes Portfolio - Lupin
Mumbai, December 30, 2024: Global pharma major Lupin Limited (Lupin) announced today the acquisition of Huminsulin® in India from Eli Lilly and Company (Lilly) to further enhance its diabetes portfolio.Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing ...
LUPN.NS - | Stock Price & Latest News | Reuters
3 days ago · Get Lupin Ltd (LUPN.NS) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments
Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio
Dec 31, 2024 · Lupin Limited. (Image Credits: FE.com) ... Download the Financial Express App for the latest finance news. First published on: 31-12-2024 at 12:47 IST . Stock Market Stats. Market Stats.
Lupin : December 13, 2024 Lupin Acquires 3 Trademarks from …
Mumbai, December 13, 2024: Global pharma major Lupin Limited (Lupin) announced today the acquisition of anti-diabetes trademarks GIBTULIO®, GIBTULIO MET® and AJADUO® from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country.
Lupin Ltd | Reuters
Aug 7, 2024 · Indian generic drugmaker Lupin reported a smaller-than-expected rise in fourth-quarter profit on Monday, as higher raw material costs more than offset strong demand for its …
Lupin Ltd (BOM:500257) Q2 FY25 Earnings Call Highlights: Strong …
Nov 9, 2024 · Lupin Ltd (BOM:500257) reported double-digit revenue growth, driven by strong commercial execution and new product launches. The company achieved a 510 basis points improvement in EBITDA...
Lupin up 2%, hits new high on buying Eli Lilly's diabetes drug ...
Dec 31, 2024 · Home / Markets / News / Lupin up 2%, hits new high on buying Eli Lilly's diabetes drug ... Lupin's management believes the company’s product pipeline for the US in FY26 will increase US sales to $1 billion in CC terms. Hence, the brokerage firm expects Lupin’s sales to grow at a compound annual growth rate (CAGR) of 9 per cent and earnings ...
Lupin Ltd. News, Corporate filings and Earnings/Conference Calls
Dec 16, 2024 · Keep track of all breaking news and updates on Lupin Ltd. from all sources in a single place. Emkay analysts have maintained a buy rating on Lupin with a target price of 2,750 per share. Lupin Acquires Huminsulin from Eli Lilly and Company to further enhance Diabetes portfolio. Intimation regarding closure of trading window.